Christopher Williams - Compass Pathways Chief Officer
| CMPS Stock | USD 3.49 0.08 2.35% |
Insider
Christopher Williams is Chief Officer of Compass Pathways Plc
| Phone | 44 71 6676 6461 |
| Web | https://compasspathways.com |
Christopher Williams Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Williams against Compass Pathways stock is an integral part of due diligence when investing in Compass Pathways. Christopher Williams insider activity provides valuable insight into whether Compass Pathways is net buyers or sellers over its current business cycle. Note, Compass Pathways insiders must abide by specific rules, including filing SEC forms every time they buy or sell Compass Pathways'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Williams over two weeks ago Acquisition by Christopher Williams of 203 shares of Union Pacific subject to Rule 16b-3 | ||
Christopher Williams over six months ago Acquisition by Christopher Williams of tradable shares of Ameriprise Financial subject to Rule 16b-3 |
Compass Pathways Management Efficiency
The company has return on total asset (ROA) of (0.3522) % which means that it has lost $0.3522 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6468) %, meaning that it created substantial loss on money invested by shareholders. Compass Pathways' management efficiency ratios could be used to measure how well Compass Pathways manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lisa Dombro | agilon health | 52 | |
| Mihran Naljayan | DaVita HealthCare Partners | N/A | |
| Jon Bates | US Physicalrapy | 54 | |
| Adam Holton | Amedisys | 53 | |
| Dan Peoples | Enhabit | N/A | |
| Veeral Desai | agilon health | 43 | |
| Michelle Gourdine | agilon health | 57 | |
| Sebastian Biedenkopf | Fresenius SE Co | 59 | |
| Theodore Halkias | agilon health | 52 | |
| Paula Price | DaVita HealthCare Partners | 59 | |
| ATC PT | US Physicalrapy | N/A | |
| Kenneth Smith | DaVita HealthCare Partners | 43 | |
| J Abernathy | National HealthCare | 83 | |
| Helen Giza | Fresenius SE Co | 55 | |
| PT MBA | Enhabit | N/A | |
| Vicki Dodson | National HealthCare | 63 | |
| Sharad Mansukani | agilon health | 51 | |
| Anne Motsenbocker | US Physicalrapy | 59 | |
| Michael Smith | agilon health | 71 | |
| Richard Schnall | agilon health | 50 | |
| William Wulf | agilon health | 60 | |
Management Performance
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.35 |
Compass Pathways Plc Leadership Team
Elected by the shareholders, the Compass Pathways' board of directors comprises two types of representatives: Compass Pathways inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compass. The board's role is to monitor Compass Pathways' management team and ensure that shareholders' interests are well served. Compass Pathways' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compass Pathways' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Teri MBA, Principal CFO | ||
| Guy Goodwin, Chief Officer | ||
| Trevor Mill, Chief Officer | ||
| Christopher Williams, Chief Officer | ||
| MBA MA, Chief Officer | ||
| Anne Benedict, Chief Officer | ||
| Ekaterina MD, CoFounder Director | ||
| Lars Wilde, Senior Advisor | ||
| Susan Stansfield, Advisor | ||
| George Goldsmith, Chairman Cofounder | ||
| Michael Falvey, Chief Officer | ||
| MaryRose Hughes, Principal CFO | ||
| Greg Ryslik, Engineering, AI | ||
| Stephen Schultz, Senior Relations | ||
| Matthew Owens, General Officer | ||
| MSc MD, Chief Officer |
Compass Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compass Pathways a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 148.2 M | ||||
| Shares Outstanding | 92.44 M | ||||
| Shares Owned By Insiders | 16.39 % | ||||
| Shares Owned By Institutions | 35.83 % | ||||
| Number Of Shares Shorted | 3.89 M | ||||
| Price To Book | 1.67 X | ||||
| EBITDA | (123.8 M) | ||||
| Net Income | (118.46 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Compass Stock Analysis
When running Compass Pathways' price analysis, check to measure Compass Pathways' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Pathways is operating at the current time. Most of Compass Pathways' value examination focuses on studying past and present price action to predict the probability of Compass Pathways' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Pathways' price. Additionally, you may evaluate how the addition of Compass Pathways to your portfolios can decrease your overall portfolio volatility.